Cargando…

Risk of respiratory depression with opioids and concomitant gabapentinoids

INTRODUCTION: The combination of opioids and central nervous system depressants such as benzodiazepines and barbiturates has an additive effect on the frequency of oversedation and respiratory depression requiring naloxone use in hospitalized patients. Gabapentinoids (gabapentin and pregabalin) are...

Descripción completa

Detalles Bibliográficos
Autores principales:	Savelloni, Julie, Gunter, Heather, Lee, Kelly C, Hsu, Chih, Yi, Cassia, Edmonds, Kyle P, Furnish, Timothy, Atayee, Rabia S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5691933/ https://www.ncbi.nlm.nih.gov/pubmed/29180889 http://dx.doi.org/10.2147/JPR.S144963

Ejemplares similares

Risk of respiratory depression with opioids and concomitant gabapentinoids [Corrigendum]
Publicado: (2018)

Clinical utility of naloxegol in the treatment of opioid-induced constipation
por: Bruner, Heather C, et al.
Publicado: (2015)

Opioid and gabapentinoid prescriptions in England from 2015 to 2020
por: Xia, Yixue, et al.
Publicado: (2022)

Trends in the Use of Gabapentinoids and Opioids in the Postoperative Period Among Older Adults
por: Bongiovanni, Tasce, et al.
Publicado: (2023)

The effect of opioid analgesics, benzodiazepines, gabapentinoids, and opioid agonist treatment on mortality risk among opioid-dependent people.
por: Bharat, Chrianna, et al.
Publicado: (2022)

Retrospective analysis reveals significant association of hypoglycemia with tramadol and methadone in contrast to other opioids
por: Makunts, Tigran, et al.
Publicado: (2019)

Association of Gabapentinoids With the Risk of Opioid-Related Adverse Events in Surgical Patients in the United States
por: Bykov, Katsiaryna, et al.
Publicado: (2020)

Characterization of hospitalized patients who received naloxone while receiving opioids with or without gabapentinoids
por: Desai, Payal H., et al.
Publicado: (2021)

A study of the reasons for prescribing and misuse of gabapentinoids in prison including their co-prescription with opioids and antidepressants
por: Soni, Anju, et al.
Publicado: (2021)

Overuse of the psychoactive analgesics’ opioids and gabapentinoid drugs in patients having surgery for nerve entrapment disorders
por: Dahlin, Lars B., et al.
Publicado: (2023)

Current Evidence on Abuse and Misuse of Gabapentinoids
por: Hägg, Staffan, et al.
Publicado: (2020)

Geographic Variation in the Use of Gabapentinoids and Opioids for Pain in a Commercially Insured Adult Population in the United States
por: Zhao, Danni, et al.
Publicado: (2022)

Gabapentinoids: Gabapentin and Pregabalin for Postoperative Pain Management
por: Imani, Farnad, et al.
Publicado: (2012)

Fatalities associated with gabapentinoids in England (2004–2020)
por: Kalk, Nicola J., et al.
Publicado: (2022)

A snapshot on the usage pattern of gabapentinoids in Oman
por: Badi, Abdulaziz Said Al, et al.
Publicado: (2022)

Risk of major adverse events associated with gabapentinoid and opioid combination therapy: A systematic review and meta-analysis
por: Hahn, Jongsung, et al.
Publicado: (2022)

Gabapentinoid Benefit and Risk Stratification: Mechanisms Over Myth
por: McAnally, Heath, et al.
Publicado: (2020)

Gabapentinoids for Pruritus in Older Adults: A Narrative Review
por: Sreekantaswamy, Shreya A., et al.
Publicado: (2021)

Gabapentinoid-related deaths: An alarming global trend or just a special challenge within the long tail of the giant opioid epidemic?
por: Bonnet, Udo, et al.
Publicado: (2022)

Correction to: Gabapentinoid Benefit and Risk Stratification: Mechanisms Over Myth
por: McAnally, Heath, et al.
Publicado: (2020)

Gabapentinoid Prescribing Practices at a Large Academic Medical Center
por: Huang, Linda L., et al.
Publicado: (2023)

Countering opioid-induced respiratory depression by non-opioids that are respiratory stimulants
por: Imam, Mohammad Zafar, et al.
Publicado: (2020)

Gabapentinoid Abuse in France: Evidence on Health Consequences and New Points of Vigilance
por: Tambon, Marine, et al.
Publicado: (2021)

Response to Comment on “Gabapentinoid Benefit and Risk Stratification: Mechanisms Over Myth”
por: McAnally, Heath B., et al.
Publicado: (2021)

Considerations When Using Gabapentinoids to Treat Trigeminal Neuralgia: A Review
por: De Stefano, Gianfranco, et al.
Publicado: (2023)

Dispensations of benzodiazepines, z-hypnotics, and gabapentinoids to patients receiving opioid agonist therapy; a prospective cohort study in Norway from 2013 to 2017
por: Vold, Jørn Henrik, et al.
Publicado: (2020)

Proton-pump inhibitor use is associated with a broad spectrum of neurological adverse events including impaired hearing, vision, and memory
por: Makunts, Tigran, et al.
Publicado: (2019)

Clinical efficacy and tolerability of Gabapentinoids with current prescription patterns in patients with Neuropathic pain
por: Shaheen, Abida, et al.
Publicado: (2019)

Effectiveness of Gabapentinoids for Cancer-related Rectal and Vesical Tenesmus: Report of Four Cases
por: Tagami, Keita, et al.
Publicado: (2020)

Non-medical Use of Prescription Gabapentinoids (Gabapentin and Pregabalin) in Five European Countries
por: Fonseca, Francina, et al.
Publicado: (2021)

Letter to the Editor: Comment on “Gabapentinoid Benefit and Risk Stratification: Mechanisms Over Myth”
por: Peckham, Alyssa M., et al.
Publicado: (2021)

The importance of cache domains in α(2)δ proteins and the basis for their gabapentinoid selectivity
por: Page, Karen M, et al.
Publicado: (2023)

Mirogabalin, a selective gabapentinoid for managing neuropathic pain—A curtain raiser
por: Nair, Abhijit
Publicado: (2022)

The Clinical Application and Progress of Mirogabalin on Neuropathic Pain as a Novel Selective Gabapentinoids
por: Tang, Hui, et al.
Publicado: (2023)

Opioid-induced respiratory depression: reversal by non-opioid drugs
por: van der Schier, Rutger, et al.
Publicado: (2014)

Opioids and Gabapentinoids Utilisation and Their Related-Mortality Trends in the United Kingdom Primary Care Setting, 2010–2019: A Cross-National, Population-Based Comparison Study
por: Kurdi, Amanj
Publicado: (2021)

Mechanisms of the gabapentinoids and α (2) δ‐1 calcium channel subunit in neuropathic pain
por: Patel, Ryan, et al.
Publicado: (2016)

Mirogabalin as a Novel Gabapentinoid for the Treatment of Chronic Pain Conditions: An Analysis of Current Evidence
por: Chen, Eric Y., et al.
Publicado: (2021)

Publisher Correction: Population scale data reveals the antidepressant effects of ketamine and other therapeutics approved for non-psychiatric indications
por: Cohen, Isaac V., et al.
Publicado: (2017)

Population scale data reveals the antidepressant effects of ketamine and other therapeutics approved for non-psychiatric indications
por: Cohen, Isaac V., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_hsq08hpvb5iri2aks7ga29o8uf